{"parse":{"title":"Investigator's brochure","pageid":7193210,"revid":782383446,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"plainlinks metadata ambox ambox-content ambox-Refimprove\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><div style=\"width:52px\"><a href=\"/wiki/File:Question_book-new.svg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png\" width=\"50\" height=\"39\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/75px-Question_book-new.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/100px-Question_book-new.svg.png 2x\" data-file-width=\"512\" data-file-height=\"399\" /></a></div></td><td class=\"mbox-text\"><div class=\"mbox-text-span\">This article <b>needs additional citations for <a href=\"/wiki/Wikipedia:Verifiability\" title=\"Wikipedia:Verifiability\">verification</a></b>.<span class=\"hide-when-compact\"> Please help <a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Investigator%27s_brochure&amp;action=edit\">improve this article</a> by <a href=\"/wiki/Help:Introduction_to_referencing_with_Wiki_Markup/1\" title=\"Help:Introduction to referencing with Wiki Markup/1\">adding citations to reliable sources</a>. Unsourced material may be challenged and removed.</span>  <small><i>(September 2009)</i></small><small class=\"hide-when-compact\"><i> (<a href=\"/wiki/Help:Maintenance_template_removal\" title=\"Help:Maintenance template removal\">Learn how and when to remove this template message</a>)</i></small></div></td></tr></tbody></table>\n<p>In <a href=\"/wiki/Drug_development\" title=\"Drug development\">drug development</a>, the <b>Investigator's Brochure</b> (<b>IB</b>) is a comprehensive document summarizing the body of information about an investigational product (\"IP\" or \"study drug\") obtained during a <a href=\"/wiki/Drug_trial\" class=\"mw-redirect\" title=\"Drug trial\">drug trial</a>. The IB is a document of critical importance throughout the drug development process and is updated with new information as it becomes available. The purpose of the IB is to compile data relevant to studies of the IP in human subjects gathered during preclinical and other clinical trials.\n</p><p>An IB is intended to provide the investigator with insights necessary for management of study conduct and study subjects throughout a clinical trial. An IB may introduce key aspects and safety measures of a <a href=\"/wiki/Clinical_trial_protocol\" class=\"mw-redirect\" title=\"Clinical trial protocol\">clinical trial protocol</a>, such as:\n</p>\n<ul><li>Dose (of the study drug)</li>\n<li>Frequency of dosing interval</li>\n<li>Methods of administration</li>\n<li>Safety monitoring procedures</li></ul>\n<p>An IB contains a \"Summary of Data and Guidance for the Investigator\" section, of which the overall aim is to \"provide the investigator with a clear understanding of the possible risks and adverse reactions, and of the specific tests, observations, and precautions that may be needed for a clinical trial. This understanding should be based on the available physical, chemical, pharmaceutical, pharmacological, toxicological, and clinical information on the investigational product(s). Guidance should also be provided to the clinical investigator on the recognition and treatment of possible overdose and adverse drug reactions that is based on previous human experience and on the pharmacology of the investigational product\".<sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup>\n</p><p>The sponsor is responsible for keeping the information in the IB up-to-date. The IB should be reviewed annually and must be updated when any new and important information becomes available, such as when a drug has received marketing approval and can be prescribed for use commercially.\n</p><p>Owing to the importance of the IB in maintaining the safety of human subjects in clinical trials, and as part of their guidance on <b><a href=\"/wiki/Good_clinical_practice\" title=\"Good clinical practice\">good clinical practice (GCP)</a></b>, the <b><a href=\"/wiki/U.S._Food_and_Drug_Administration\" class=\"mw-redirect\" title=\"U.S. Food and Drug Administration\">U.S. Food and Drug Administration (FDA)</a></b> has written regulatory codes and guidances for authoring the IB, and <a href=\"/wiki/International_Conference_on_Harmonisation_of_Technical_Requirements_for_Registration_of_Pharmaceuticals_for_Human_Use\" class=\"mw-redirect\" title=\"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use\">the <b>International Conference on Harmonisation (ICH)</b></a> has prepared a detailed guidance for the authoring of the IB in the <a href=\"/wiki/European_Union\" title=\"European Union\">European Union</a> (<b>EU</b>), <a href=\"/wiki/Japan\" title=\"Japan\">Japan</a>, and the <a href=\"/wiki/United_States\" title=\"United States\">United States</a> (<b>US</b>).<sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Guidance_documents\">Guidance documents</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Investigator%27s_brochure&amp;action=edit&amp;section=1\" title=\"Edit section: Guidance documents\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>As part of its guidance on <a href=\"/wiki/Good_Clinical_Practice\" class=\"mw-redirect\" title=\"Good Clinical Practice\">Good Clinical Practice</a> (<b>GCP</b>), the International Conference on Harmonisation (<b>ICH</b>) has prepared a detailed guidance for the contents of the IB in the European Union (<b>EU</b>), Japan, and the United States (<b>US</b>).<a rel=\"nofollow\" class=\"external autonumber\" href=\"http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073122.pdf\">[1]</a>\n</p><p>If many clinical trials have been completed, tables that summarize findings across the various studies can be very useful to demonstrate outcomes in, e.g., different patient populations or different indications.\n</p>\n<ul><li>Code of Federal Regulations, Title 21, Part 312, Investigational New Drug Application <a rel=\"nofollow\" class=\"external autonumber\" href=\"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=312.23\">[2]</a></li>\n<li>Code of Federal Regulations, Title 21, Part 201.56 (and Part 201.57) <a rel=\"nofollow\" class=\"external autonumber\" href=\"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=201.56\">[3]</a></li>\n<li>CDER Guidance for Industry. Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products&#160;\u2014 Content and Format. <a rel=\"nofollow\" class=\"external autonumber\" href=\"http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM075057.pdf\">[4]</a></li>\n<li>CDER Guidance for Industry. Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products&#160;\u2014 Content and Format. <a rel=\"nofollow\" class=\"external autonumber\" href=\"http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM075057.pdf\">[5]</a></li>\n<li>CDER Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. <a rel=\"nofollow\" class=\"external autonumber\" href=\"http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf\">[6]</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Investigator%27s_brochure&amp;action=edit&amp;section=2\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/Directive_2001/20/EC\" class=\"mw-redirect\" title=\"Directive 2001/20/EC\">Directive 2001/20/EC</a> (Europe)</li>\n<li><a href=\"/wiki/Directive_2005/28/EC\" class=\"mw-redirect\" title=\"Directive 2005/28/EC\">Directive 2005/28/EC</a> (Europe)</li>\n<li><a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">Clinical trial</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Investigator%27s_brochure&amp;action=edit&amp;section=3\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap\"><ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/08/WC500191488.pdf\">http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/08/WC500191488.pdf</a> ICH GCP guidelines</span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073122.pdf\">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073122.pdf</a></span>\n</li>\n</ol></div></div>\n<ul><li>International Conference on Harmonisation (<b>ICH</b>) Topic E6-Guideline for Good Clinical Practice <a rel=\"nofollow\" class=\"external autonumber\" href=\"http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073122.pdf\">[7]</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.gcphelpdesk.com\">gcp investigator brochure</a></li></ul>\n\n<!-- \nNewPP limit report\nParsed by mw2164\nCached time: 20180916032709\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.096 seconds\nReal time usage: 0.129 seconds\nPreprocessor visited node count: 165/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 4313/2097152 bytes\nTemplate argument size: 105/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 1/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 1020/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.032/10.000 seconds\nLua memory usage: 836 KB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%   96.068      1 -total\n 77.05%   74.023      1 Template:Refimprove\n 47.46%   45.595      1 Template:Ambox\n 19.48%   18.717      1 Template:Reflist\n  5.12%    4.916      1 Template:Main_other\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:7193210-0!canonical and timestamp 20180916032709 and revision id 782383446\n -->\n</div>"},"langlinks":[{"lang":"es","url":"https://es.wikipedia.org/wiki/Manual_del_investigador","langname":"Spanish","autonym":"espa\u00f1ol","*":"Manual del investigador"},{"lang":"pl","url":"https://pl.wikipedia.org/wiki/Broszura_badacza","langname":"Polish","autonym":"polski","*":"Broszura badacza"}],"categories":[{"sortkey":"","hidden":"","*":"Articles_needing_additional_references_from_September_2009"},{"sortkey":"","hidden":"","*":"All_articles_needing_additional_references"},{"sortkey":"","*":"Clinical_research"},{"sortkey":"","*":"Clinical_trials"},{"sortkey":"","*":"Good_clinical_practice"}],"links":[{"ns":14,"exists":"","*":"Category:Articles needing additional references from September 2009"},{"ns":0,"exists":"","*":"Clinical trial"},{"ns":0,"exists":"","*":"Clinical trial protocol"},{"ns":0,"exists":"","*":"Directive 2001/20/EC"},{"ns":0,"exists":"","*":"Directive 2005/28/EC"},{"ns":0,"exists":"","*":"Drug development"},{"ns":0,"exists":"","*":"Drug trial"},{"ns":0,"exists":"","*":"European Union"},{"ns":0,"exists":"","*":"Good Clinical Practice"},{"ns":0,"exists":"","*":"Good clinical practice"},{"ns":0,"exists":"","*":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use"},{"ns":0,"exists":"","*":"Japan"},{"ns":0,"exists":"","*":"U.S. Food and Drug Administration"},{"ns":0,"exists":"","*":"United States"},{"ns":4,"exists":"","*":"Wikipedia:Verifiability"},{"ns":12,"exists":"","*":"Help:Introduction to referencing with Wiki Markup/1"},{"ns":12,"exists":"","*":"Help:Maintenance template removal"}],"templates":[{"ns":10,"exists":"","*":"Template:Refimprove"},{"ns":10,"exists":"","*":"Template:More citations needed"},{"ns":10,"exists":"","*":"Template:Ambox"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Message box"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Message box/configuration"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":["Question_book-new.svg"],"externallinks":["http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/08/WC500191488.pdf","http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073122.pdf","https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=312.23","https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=201.56","http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM075057.pdf","http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf","http://www.gcphelpdesk.com"],"sections":[{"toclevel":1,"level":"2","line":"Guidance documents","number":"1","index":"1","fromtitle":"Investigator's_brochure","byteoffset":2844,"anchor":"Guidance_documents"},{"toclevel":1,"level":"2","line":"See also","number":"2","index":"2","fromtitle":"Investigator's_brochure","byteoffset":4507,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"3","index":"3","fromtitle":"Investigator's_brochure","byteoffset":4614,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Investigator's brochure","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q9180065"}]}}